A PHASE II TRIAL OF DOXIL, RITUXIMAB, CYCLOPHOSPHAMIDE, VINCRISTINE, AND PREDNIS

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 具体目标： 主要目标： " 目的探讨DR-COP方案治疗初治艾滋病相关淋巴瘤的有效率（CR + CRu + PR）。 " 确定接受DR-COP治疗的患者的缓解持续时间（DR）（无复发生存期）。 " 确定接受DR-COP治疗的患者的中位生存时间。 " 确定接受DR-COP治疗的患者中细菌、真菌和机会性感染的发生率。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SPECIFIC AIMS: Primary Aims: " To determine the response rate (CR + CRu + PR) to DR-COP in patients with newly-diagnosed AIDS-related lymphoma. " To determine the duration of response (DR) (relapse-free survival) of patients treated with DR-COP. " To determine the median survival time of patients treated with DR-COP. " To determine rate of bacterial, fungal and opportunistic infections in patients treated with DR-COP.